Cargando…
Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review
BACKGROUND: IgA nephropathy is the most common primary glomerular disease worldwide and also the most frequent cause of kidney failure. Mycophenolate mofetil (MMF) is a selective immunosuppressant widely used in many autoimmune diseases. However, the benefits and risks of MMF for the treatment of Ig...
Autores principales: | Chen, Youyuan, Li, YuMin, Yang, ShengLin, Li, Yan, Liang, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267433/ https://www.ncbi.nlm.nih.gov/pubmed/25475967 http://dx.doi.org/10.1186/1471-2369-15-193 |
Ejemplares similares
-
Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
por: Du, Bing, et al.
Publicado: (2017) -
Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials
por: Zheng, Jian-Nan, et al.
Publicado: (2018) -
Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children
por: Kang, Zhijuan, et al.
Publicado: (2015) -
Mycophenolate Mofetil for Severe IgA Vasculitis Nephropathy in Children: An Observational Study
por: Samsonov, Dmitry, et al.
Publicado: (2022) -
A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]
por: Hogg, Ronald J, et al.
Publicado: (2004)